[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS65411B1 - Jedinjenja neuroatenuirajućeg norketamina i metodi - Google Patents

Jedinjenja neuroatenuirajućeg norketamina i metodi

Info

Publication number
RS65411B1
RS65411B1 RS20240383A RSP20240383A RS65411B1 RS 65411 B1 RS65411 B1 RS 65411B1 RS 20240383 A RS20240383 A RS 20240383A RS P20240383 A RSP20240383 A RS P20240383A RS 65411 B1 RS65411 B1 RS 65411B1
Authority
RS
Serbia
Prior art keywords
neuro
methods
attenuating norketamine
compounds
norketamine compounds
Prior art date
Application number
RS20240383A
Other languages
English (en)
Inventor
Alex Nivorozhkin
Nelson Landrau
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of RS65411B1 publication Critical patent/RS65411B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20240383A 2014-11-04 2015-11-04 Jedinjenja neuroatenuirajućeg norketamina i metodi RS65411B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
EP15856205.8A EP3215147B1 (en) 2014-11-04 2015-11-04 Neuro-attenuating norketamine compounds and methods

Publications (1)

Publication Number Publication Date
RS65411B1 true RS65411B1 (sr) 2024-05-31

Family

ID=55909773

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240383A RS65411B1 (sr) 2014-11-04 2015-11-04 Jedinjenja neuroatenuirajućeg norketamina i metodi

Country Status (18)

Country Link
US (5) US10252982B2 (sr)
EP (2) EP3215147B1 (sr)
JP (2) JP6882180B2 (sr)
KR (1) KR102604397B1 (sr)
CN (2) CN107106529A (sr)
AU (1) AU2015343083B2 (sr)
CA (1) CA2966737A1 (sr)
DK (1) DK3215147T3 (sr)
ES (1) ES2977383T3 (sr)
FI (1) FI3215147T3 (sr)
HU (1) HUE066468T2 (sr)
LT (1) LT3215147T (sr)
PL (1) PL3215147T3 (sr)
PT (1) PT3215147T (sr)
RS (1) RS65411B1 (sr)
RU (1) RU2771275C2 (sr)
SI (1) SI3215147T1 (sr)
WO (1) WO2016073653A1 (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
CN108884019A (zh) * 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
US20190256487A1 (en) * 2016-09-16 2019-08-22 BioPharmaWorks, LLC Hydroxynorketamine prodrugs
EP3533444A4 (en) * 2016-10-27 2020-05-20 National University Corporation Chiba University PHARMACEUTICAL APPLICATIONS OF (N) -NORKETAMINE AND ITS SALTS
WO2018191482A2 (en) 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
ES2797381T3 (es) 2017-07-31 2020-12-02 Small Pharma Ltd Formas cristalinas de hidroxinorcetamina
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
WO2020194087A2 (en) 2019-03-25 2020-10-01 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
TW202208373A (zh) * 2020-05-20 2022-03-01 美商瑟泰戈治療學股份有限公司 環經氘化之加波沙朵及其用於治療精神病症用途
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
EP4329737A1 (en) * 2021-04-30 2024-03-06 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1567145B1 (en) * 2002-11-18 2009-06-03 Yaupon Therapeutics, Inc. Analgesic uses of (s)-norketamine
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
EP2139848A1 (en) * 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US8710070B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
JP2016531913A (ja) 2013-08-26 2016-10-13 アモーサ セラピューティックス, インコーポレイテッドAmorsa Therapeutics, Inc. 神経抑制性ケタミンの単層による経口投与
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi

Also Published As

Publication number Publication date
HUE066468T2 (hu) 2024-08-28
US11603348B2 (en) 2023-03-14
US20230192593A1 (en) 2023-06-22
US10981859B2 (en) 2021-04-20
AU2015343083A1 (en) 2017-06-08
AU2015343083B2 (en) 2020-07-23
EP3215147A1 (en) 2017-09-13
PT3215147T (pt) 2024-04-18
CN107106529A (zh) 2017-08-29
US20220402863A1 (en) 2022-12-22
US20190263749A1 (en) 2019-08-29
US10252982B2 (en) 2019-04-09
RU2017119222A (ru) 2018-12-06
CA2966737A1 (en) 2016-05-12
SI3215147T1 (sl) 2024-05-31
FI3215147T3 (fi) 2024-04-18
US11613515B2 (en) 2023-03-28
ES2977383T3 (es) 2024-08-22
RU2017119222A3 (sr) 2019-06-07
US20170355663A1 (en) 2017-12-14
KR102604397B1 (ko) 2023-11-21
JP6882180B2 (ja) 2021-06-02
JP2018501299A (ja) 2018-01-18
DK3215147T3 (da) 2024-04-02
EP3215147A4 (en) 2018-05-30
US20220106258A1 (en) 2022-04-07
PL3215147T3 (pl) 2024-06-24
JP2021120389A (ja) 2021-08-19
CN115521217A (zh) 2022-12-27
EP3215147B1 (en) 2024-02-28
EP4393487A3 (en) 2024-08-21
KR20170083575A (ko) 2017-07-18
LT3215147T (lt) 2024-04-25
RU2771275C2 (ru) 2022-04-29
WO2016073653A1 (en) 2016-05-12
EP4393487A2 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
HUE066468T2 (hu) Idegnyugtató norketamin vegyületek és eljárások
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB201413086D0 (en) Methods
SG11201704473WA (en) New methods and uses
HK1243342A1 (zh) 化合物和方法
GB201608779D0 (en) Methods and compounds
GB201608776D0 (en) Methods and compounds
GB201408745D0 (en) Methods
HK1220676A1 (zh) 配置件和方法
GB201419650D0 (en) Modified heterocyclase
GB201415250D0 (en) Compound and method
GB201408091D0 (en) Methods and uses
EP3185901C0 (en) COMPOUND AND METHOD
DK3145380T3 (en) Toiletventilationssystem
GB201415685D0 (en) Methods
AU5286P (en) FLOMANWHW Mandevilla sanderi
GB201404301D0 (en) Compounds and combinations
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses
GB201414122D0 (en) Methods
GB201420773D0 (en) Compound and method
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201406991D0 (en) Methods